Nitrendipine nanocrystals: Its preparation, characterization, and in vitro-in vivo evaluation

AAPS PharmSciTech

Volumn 12, Issue 4, 2011, Pages 1136-1143

  Quan, Peng ^a   Xia, Dengning ^a   Piao, Hongze ^a   Piao, Hongyu ^a   Shi, Kai ^a   Jia, Yinnong ^a   Cui, Fude ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

bioavailability; dissolution; nanocrystals; nanotechnology; nitrendipine

Indexed keywords

ACETONE; NANOCRYSTAL; NITRENDIPINE; POLYVINYL ALCOHOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; SPRAY DRYING; TABLET; X RAY DIFFRACTION;

ACETONE; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG COMPOUNDING; KINETICS; MALE; NANOPARTICLES; NANOTECHNOLOGY; NITRENDIPINE; PARTICLE SIZE; POLYVINYL ALCOHOL; RATS; RATS, WISTAR; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 83555164831     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9682-2     Document Type: Article

References (38)

1. RA Prentis Y Lis SR Walker 1988 Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br J Clin Pharmacol 25 3 387 396 3358900 1:STN:280:DyaL1c7ptlShtQ%3D%3D
2. GL Amidon H Lennernas VP Shah JR Crison 1995 A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 3 413 420 7617530 10.1023/A:1016212804288 1:CAS:528:DyaK2MXksVGqur8%3D
3. AA Date VB Patravale 2004 Current strategies for engineering drug nanoparticles Curr Opin Colloid Interface Sci 9 222 235 10.1016/j.cocis.2004.06. 009 1:CAS:528:DC%2BD2cXhtVChurvK (Pubitemid 39586699)
4. L Gao D Zhang M Chen C Duan W Dai L Jia, et al. 2008 Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions Int J Pharm 355 1-2 321 327 18242896 10.1016/j.ijpharm.2007.12.016 1:CAS:528: DC%2BD1cXkt1ygsbs%3D
5. BE Rabinow 2004 Nanosuspensions in drug delivery Nat Rev Drug Discov 3 9 785 796 15340388 10.1038/nrd1494 1:CAS:528:DC%2BD2cXntFCns7o%3D (Pubitemid 39242830)
6. VB Patravale AA Date RM Kulkarni 2004 Nanosuspensions: a promising drug delivery strategy J Pharm Pharmacol 56 7 827 840 15233860 10.1211/0022357023691 1:CAS:528:DC%2BD2cXmtFGqtL8%3D (Pubitemid 38885975)
7. JE Kipp 2004 The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs Int J Pharm 284 1-2 109 122 15454302 10.1016/j.ijpharm.2004.07.019 1:CAS:528:DC%2BD2cXnvVCjurw%3D (Pubitemid 39349144)
8. B Van Eerdenbrugh J Vermant JA Martens L Froyen J Van Humbeeck P Augustijns, et al. 2009 A screening study of surface stabilization during the production of drug nanocrystals J Pharm Sci 98 6 2091 2103 18803265 10.1002/jps.21563
9. J Pardeike RH Muller 2010 Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18 Int J Pharm 391 1-2 322 329 20214969 10.1016/j.ijpharm.2010.03.002 1:CAS:528:DC%2BC3cXltFCntrw%3D
10. S Verma BD Huey DJ Burgess 2009 Scanning probe microscopy method for nanosuspension stabilizer selection Langmuir 25 21 12481 12487 19791747 10.1021/la9016432 1:CAS:528:DC%2BD1MXht1SnsbbP
11. X Li L Gu Y Xu Y Wang 2009 Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats Drug Dev Ind Pharm 35 7 827 833 19466879 10.1080/03639040802623941 1:CAS:528:DC%2BD1MXnt1Sitbw%3D
12. S Verma R Gokhale DJ Burgess 2009 A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions Int J Pharm 380 1-2 216 222 19596059 10.1016/j.ijpharm.2009.07.005 1:CAS:528: DC%2BD1MXhtV2hsbzF
13. R Shegokar RH Muller 2010 Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives Int J Pharm 399 1-2 129 139 20674732 10.1016/j.ijpharm.2010.07.044 1:CAS:528: DC%2BC3cXhtFOisbzM
14. C Jacobs RH Muller 2002 Production and characterization of a budesonide nanosuspension for pulmonary administration Pharm Res 19 2 189 194 11883646 10.1023/A:1014276917363 1:CAS:528:DC%2BD38XitVSlsro%3D (Pubitemid 34165405)
15. J Moschwitzer G Achleitner H Pomper RH Muller 2004 Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology Eur J Pharm Biopharm 58 3 615 619 15451536 10.1016/j.ejpb.2004.03.022 (Pubitemid 39297108)
16. R Xiong W Lu J Li P Wang R Xu T Chen 2008 Preparation and characterization of intravenously injectable nimodipine nanosuspension Int J Pharm 350 1-2 338 343 17920794 10.1016/j.ijpharm.2007.08.036 1:CAS:528:DC%2BD1cXhtlGnu74%3D
17. KP Krause O Kayser K Mader R Gust RH Muller 2000 Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation Int J Pharm 196 2 169 172 10699711 10.1016/S0378-5173(99)00414-7 1:CAS:528: DC%2BD3cXhtl2qt70%3D (Pubitemid 30105736)
18. MA Kassem AA Abdel Rahman MM Ghorab MB Ahmed RM Khalil 2007 Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs Int J Pharm 340 1-2 126 133 17600645 10.1016/j.ijpharm.2007.03.011 1:CAS:528:DC%2BD2sXns1Kgsr0%3D (Pubitemid 47043351)
19. CM Keck RH Muller 2006 Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur J Pharm Biopharm 62 1 3 16 16129588 10.1016/j.ejpb.2005.05.009 1:CAS:528:DC%2BD2MXht1Ontb7E (Pubitemid 41736019)
20. PR Mishra L Al Shaal RH Muller CM Keck 2009 Production and characterization of Hesperetin nanosuspensions for dermal delivery Int J Pharm 371 1-2 182 189 19162147 10.1016/j.ijpharm.2008.12.030 1:CAS:528: DC%2BD1MXjslWkurw%3D
21. RH Muller C Jacobs O Kayser 2001 Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future Adv Drug Deliv Rev 47 1 3 19 11251242 10.1016/S0169-409X(00)00118-6 1:CAS:528:DC%2BD3MXhvVajsr0%3D (Pubitemid 32209229)
22. RH Muller K Peters 1998 Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique Int J Pharm 160 229 237 10.1016/S0378-5173(97)00311-6 1:CAS:528:DyaK1cXot12iuw%3D%3D (Pubitemid 28083096)
23. L Wang FD Cui H Sunada 2006 Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method Chem Pharm Bull 54 1 37 43 16394546 10.1248/cpb.54.37 (Pubitemid 43036746)
24. X Pu J Sun Y Wang X Liu P Zhang X Tang, et al. 2009 Development of a chemically stable 10-hydroxycamptothecin nanosuspensions Int J Pharm 379 1 167 173 19505545 10.1016/j.ijpharm.2009.05.062 1:CAS:528:DC%2BD1MXhtVaqs7vO
25. Mersmann A, Eble A, Heyer C. Crystal Growth. In: Mersmann A, editor. Crystallization technology handbook. 2nd ed. New York: Taylor & Francis; 2001. p. 102-9.
26. S Kaneko Y Yamagami H Tochihara I Hirasawa 2002 Effect of Supersaturation on Crystal Size and Number of Crystals Produced in Antisolvent Crystallization J Chem Eng Jpn 35 11 1219 1223 10.1252/jcej.35.1219 1:CAS:528: DC%2BD38XptF2qtrw%3D (Pubitemid 36073051)
27. B Van Eerdenbrugh G Van den Mooter P Augustijns 2008 Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products Int J Pharm 364 1 64 75 18721869 10.1016/j.ijpharm.2008.07.023
28. L Gao D Zhang M Chen 2008 Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system J Nanopart Res 10 845 862 10.1007/s11051-008-9357-4 1:CAS:528:DC%2BD1cXkvFajsbg%3D
29. D Zhang T Tan L Gao W Zhao P Wang 2007 Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies Drug Dev Ind Pharm 33 5 569 575 17520449 10.1080/03639040600975147 1:CAS:528:DC%2BD2sXlsFChsr4%3D (Pubitemid 46808766)
30. V Teeranachaideekul V Junyaprasert E Souto R Muller 2008 Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology Int J Pharm 354 1-2 227 234 18242898 10.1016/j.ijpharm.2007.11.062 1:CAS:528:DC%2BD1cXjsFOqtb4%3D
31. P Kocbek S Baumgartner J Kristl 2006 Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs Int J Pharm 312 1-2 179 186 16469459 10.1016/j.ijpharm.2006.01.008 1:CAS:528:DC%2BD28XisFeqtro%3D
32. M Schmidt R Kusche Bv Issendorff H Haberland 1998 Irregular variations in themelting point of size-selected atomic clusters Nature 393 238 240 10.1038/30415 1:CAS:528:DyaK1cXjtlymtLk%3D (Pubitemid 28261715)
33. SL Lai JY Guo V Petrova G Ramanath LH Allen 1996 Size-Dependent Melting Properties of Small Tin Particles: Nanocalorimetric Measurements Phys Rev Lett 77 1 99 102 10061781 10.1103/PhysRevLett.77.99 1:CAS:528:DyaK28XjvFSgurs%3D (Pubitemid 126623970)
34. Zhang GGZ, Zhou D. Crystalline and Amorphous Solids. In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR, editors. Developing Solid Oral Dosage Forms. 1st ed. Oxford: Elsevier; 2009. p. 35-6.
35. F Kesisoglou S Panmai Y Wu 2007 Nanosizing - Oral formulation development and biopharmaceutical evaluation Adv Drug Deliv Rev 59 7 631 644 17601629 10.1016/j.addr.2007.05.003 1:CAS:528:DC%2BD2sXpsFGks7o%3D (Pubitemid 47285408)
36. RJ Hintz KC Johnson 1989 The effect of particle size distribution on dissolution rate and oral absorption Int J Pharm 51 1 9 17 10.1016/0378-5173(89) 90069-0 1:CAS:528:DyaL1MXitFyqt7c%3D (Pubitemid 19087827)
37. JU Junghanns RH Muller 2008 Nanocrystal technology, drug delivery and clinical applications Int J Nanomedicine 3 3 295 309 18990939 1:CAS:528:DC%2BD1cXhtlems7jF
38. HG Choi DD Kim HW Jun BK Yoo CS Yong 2003 Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin Drug Dev Ind Pharm 29 10 1085 1094 14677769 10.1081/DDC-120025866 1:CAS:528:DC%2BD3sXptVOru70%3D (Pubitemid 37499544)